Press-release for stocks for ELOX listed in the nasdaq exchange

Prices are updated after-hours

symbols : ELOX exchanges : Nasdaq

save search

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -18.37% | O: 2.04% H: 0.0% C: -1.27%
elx-02 zkn-013 pharmaceuticals program

Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival; Nubia Brand International Corp.; The Alkaline Water Company Inc.; DMK Pharmaceuticals Corporation; MedAvail Holdings, Inc.; InVivo Therapeutics Holdings Corp.; and ADDvantage Technologies Group, Inc. from The Nasdaq Stock Market
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
COMS | $0.2595 37.35% 720

Manufacturing

| 35.9% | O: -2.27% H: 27.46% C: 15.87%
WTER | $0.0015 14185.71% 640

Consumer Non-Durables

| 614.29% | O: 0.0% H: 614.29% C: 0.0%
NDAQ | $60.35 0.47% 0.46% 3.1M

Finance

| -0.87% | O: 0.46% H: 3.09% C: 1.11%
CETX | $3.06 -3.56% 2.7K

Electronic Technology

| -30.51% | O: 0.22% H: 1.85% C: -2.22%
water company international spac pharmaceuticals global system medical therapeutics market

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Published: 2024-03-13 (Crawled : 16:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| Email alert Add to watchlist
zkn-013 rare license pharmaceuticals dermatological agreement

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| Email alert Add to watchlist
business update pharmaceuticals financial results

Emerging Market Trends in Muscular Dystrophy: A DelveInsight Analysis of Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-girdle Muscular Dystrophy
Published: 2023-11-06 (Crawled : 22:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K

Health Technology

| 44.34% | O: 0.65% H: 4.43% C: 2.87%
RNA | $22.74 -1.3% -1.32% 1M

Health Technology

| 328.87% | O: -0.57% H: 10.72% C: 10.63%
trends market

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Published: 2023-10-09 (Crawled : 12:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -81.48% | O: -0.46% H: 4.19% C: 2.33%
elx-02 kidney pharmaceuticals study

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-09-19 (Crawled : 12:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -85.35% | O: -0.18% H: 1.83% C: 1.83%
nasdaq direct offering pharmaceuticals

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -86.39% | O: 1.87% H: 0.0% C: -8.85%
elx-02 positive pharmaceuticals results study

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -84.79% | O: 7.22% H: 0.0% C: -5.14%
elx-02 zkn-013 pharmaceuticals program

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-08-14 (Crawled : 12:20) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -83.16% | O: 5.05% H: 20.04% C: 14.83%
business update pharmaceuticals financial results

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -83.16% | O: 5.05% H: 20.04% C: 14.83%
elx-02 drug pharmaceuticals response study phase 2

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Published: 2023-08-03 (Crawled : 13:20) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -88.72% | O: 1.83% H: 0.83% C: -9.97%
nasdaq granted pharmaceuticals extension market

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
Published: 2023-07-10 (Crawled : 13:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -77.9% | O: 1.1% H: 10.11% C: 6.83%
publication pharmaceuticals platform

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
Published: 2023-06-28 (Crawled : 13:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -80.3% | O: -0.99% H: 1.0% C: -1.49%
elx-02 positive treatment pharmaceuticals results study

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
Published: 2023-06-21 (Crawled : 17:00) - globenewswire.com
ELOX | $0.94 -51.57% 93K

Health Technology

| -83.87% | O: 1.41% H: 0.9% C: -11.93%
pharmaceuticals